Voyager Therapeutics, Inc. (NASDAQ: VYGR) reported a fourth‑quarter loss of $0.46 per share, beating the consensus estimate of $0.54 per share, and generated $15.3 million in revenue, well above the $9.71 million forecast. The company’s cash balance stood at $201.7 million as of December 31 2025, giving it a runway that management expects to extend through 2028.
Collaboration revenue for the quarter rose to $15.3 million from $6.3 million in Q4 2024, while full‑year collaboration revenue fell to $40.4 million from $80.0 million in 2024. Net loss for the quarter was $27.4 million, an improvement over the $34.5 million loss reported in Q4 2024, but the full‑year net loss widened to $119.7 million from $65.0 million in 2024, largely due to changes in collaboration revenue recognition.
The company highlighted progress in its Alzheimer’s disease pipeline. The VY1706 gene‑therapy candidate is slated for first‑in‑human dosing in the second half of 2026, and data for the VY7523 anti‑tau antibody are expected in the same period. Voyager also confirmed the validation of its TRACER capsid technology and announced that two intravenous‑delivered neuro‑gene therapies will enter clinical trials in H2 2026. In addition, a murine study of the Voyager NeuroShuttle platform with an anti‑amyloid antibody demonstrated sustained brain exposure, supporting the platform’s potential for non‑viral delivery across the blood‑brain barrier.
"Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by three pillars of value creation: data on tau‑targeting assets for Alzheimer’s disease, clinical entry for our novel I.V.-delivered neuro gene therapies, and advancement of our nonviral delivery platform, Voyager NeuroShuttle," said CEO Alfred W. Sandrock, Jr. "With a strong cash position that is expected to provide runway into 2028, I believe Voyager is poised to execute across multiple clinical programs, further validate our platforms, and build a foundation for long-term shareholder value."
The earnings release was well received by investors, with analysts noting the earnings beat and the company’s robust cash position as key indicators of financial strength and continued investment in its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.